Qiagen Licenses Biomarkers for Blood Cancers | GenomeWeb

NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Thursday that it has licensed four biomarkers from the University of Tokyo that are believed to play a role in the prognosis of patients with blood cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.